Lilly’s weight-loss pill gains fda approval, rattling novo nordisk

Eli Lilly & Co. just threw down the gauntlet in the burgeoning weight-loss drug market. Foundayo, their highly anticipated oral weight-loss medication, has secured FDA approval, immediately intensifying the pressure on Novo Nordisk, the Danish pharma giant that previously held a near-monopoly with its own oral offering.

A four-month sprint to approval

The FDA’s surprisingly swift approval – a review period clocking in at under four months – is attributed to a new expedited program designed to accelerate access to promising drugs addressing critical national priorities. This move underscores the perceived importance of obesity treatments, a market estimated to balloon to over $100 billion by 2030.

Foundayo, taken once daily, is positioned to help individuals lose weight or maintain existing weight loss. Priced at a relatively accessible $149 per month for cash-paying patients, it’s slated to become available through LillyDirect, the company's direct-to-consumer platform, starting April 6th. The market reacted swiftly; Lilly shares surged as much as 5.4% in New York trading, while Novo Nordisk’s American depositary receipts dipped before staging a partial recovery.

Novo's response: semaglutide vs. orforglipron

Novo Nordisk isn't taking this challenge lying down. Jamey Millar, Head of Novo Nordisk in the U.S., recently emphasized the distinction between their offerings. “The Wegovy pill is semaglutide in a pill. Orfor is not Zepbound in a pill,” he stated, referencing the generic name for orforglipron. Novo’s strategy hinges on leveraging semaglutide, the same active ingredient found in their blockbuster injectable drugs, Ozempic and Wegovy. Despite being first to market with an oral option, Novo has seen its market share erode in recent years as more potent injectable options from Lilly gained traction.

The race is now decisively shifting to pills, offering a more cost-effective manufacturing process and improved patient convenience. Over 600,000 prescriptions for Novo’s pill have already been written, marking one of the most successful drug launches in history. Clinical trials showed an average weight loss of 13.6% over 64 weeks, a compelling figure—though Lilly counters that the 11% weight loss demonstrated in their trials is still significant.

Interestingly, while Novo’s pill may demonstrate slightly superior efficacy, it comes with more restrictive dosing requirements. Patients must consume it on an empty stomach and wait a full 30 minutes before eating or drinking. Foundayo, on the other hand, offers greater flexibility. The gastrointestinal side effects observed in both trials were largely consistent with those seen with injectable versions of these medications.

The landscape of obesity treatment is no longer defined by injections alone. Lilly’s rapid move to compete directly with Novo Nordisk signals a battle for pill supremacy, one that promises to reshape the industry and impact millions seeking healthier lives. Wall Street analysts already project Foundayo sales could reach a staggering $18 billion by 2030—a testament to the immense demand and the potential for these medications to fundamentally alter how we approach weight management.